83 related articles for article (PubMed ID: 16514157)
1. The encapsulation of enterotoxigenic Escherichia coli colonization factor CS3 in biodegradable microspheres enhances the murine antibody response following intranasal administration.
Byrd W; Cassels FJ
Microbiology (Reading); 2006 Mar; 152(Pt 3):779-786. PubMed ID: 16514157
[TBL] [Abstract][Full Text] [Related]
2. Intranasal immunization of BALB/c mice with enterotoxigenic Escherichia coli colonization factor CS6 encapsulated in biodegradable poly(DL-lactide-co-glycolide) microspheres.
Byrd W; Cassels FJ
Vaccine; 2006 Feb; 24(9):1359-66. PubMed ID: 16233937
[TBL] [Abstract][Full Text] [Related]
3. Long-term systemic and mucosal antibody responses measured in BALB/c mice following intranasal challenge with viable enterotoxigenic Escherichia coli.
Byrd W; Cassels FJ
FEMS Immunol Med Microbiol; 2006 Mar; 46(2):262-8. PubMed ID: 16487308
[TBL] [Abstract][Full Text] [Related]
4. The New World primate, Aotus nancymae, as a model for examining the immunogenicity of a prototype enterotoxigenic Escherichia coli subunit vaccine.
Jones FR; Hall ER; Tribble D; Savarino SJ; Cassels FJ; Porter C; Meza R; Nunez G; Espinoza N; Salazar M; Luckett R; Scott D
Vaccine; 2006 May; 24(18):3786-92. PubMed ID: 16343702
[TBL] [Abstract][Full Text] [Related]
5. Mucosal immunization of BALB/c mice using enterotoxigenic Escherichia coli colonization factors CFA/I and CS6 administered with and without a mutant heat-labile enterotoxin.
Byrd W; Cassels FJ
Vaccine; 2003 May; 21(17-18):1884-93. PubMed ID: 12706673
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a prototype enterotoxigenic Escherichia coli adhesin vaccine in mice and nonhuman primates.
Sincock SA; Hall ER; Woods CM; O'Dowd A; Poole ST; McVeigh AL; Nunez G; Espinoza N; Miller M; Savarino SJ
Vaccine; 2016 Jan; 34(2):284-291. PubMed ID: 26597148
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers.
Carpenter CM; Hall ER; Randall R; McKenzie R; Cassels F; Diaz N; Thomas N; Bedford P; Darsley M; Gewert C; Howard C; Sack RB; Sack DA; Chang HS; Gomes G; Bourgeois AL
Vaccine; 2006 May; 24(18):3709-18. PubMed ID: 16153753
[TBL] [Abstract][Full Text] [Related]
8. Intranasal co-administration of recombinant active fragment of Zonula occludens toxin and truncated recombinant EspB triggers potent systemic, mucosal immune responses and reduces span of E. coli O157:H7 fecal shedding in BALB/c mice.
Shekar A; Ramlal S; Jeyabalaji JK; Sripathy MH
Med Microbiol Immunol; 2019 Feb; 208(1):89-100. PubMed ID: 30209565
[TBL] [Abstract][Full Text] [Related]
9. Murine antibody response to intranasally administered enterotoxigenic Escherichia coli colonization factor CS6.
de Lorimier AJ; Byrd W; Hall ER; Vaughan WM; Tang D; Roberts ZJ; McQueen CE; Cassels FJ
Vaccine; 2003 Jun; 21(19-20):2548-55. PubMed ID: 12744890
[TBL] [Abstract][Full Text] [Related]
10. Maternal vaccination with a fimbrial tip adhesin and passive protection of neonatal mice against lethal human enterotoxigenic Escherichia coli challenge.
Luiz WB; Rodrigues JF; Crabb JH; Savarino SJ; Ferreira LC
Infect Immun; 2015 Dec; 83(12):4555-64. PubMed ID: 26371126
[TBL] [Abstract][Full Text] [Related]
11. A PLGA-encapsulated chimeric protein protects against adherence and toxicity of enterotoxigenic Escherichia coli.
Nazarian S; Gargari SL; Rasooli I; Hasannia S; Pirooznia N
Microbiol Res; 2014; 169(2-3):205-12. PubMed ID: 23906742
[TBL] [Abstract][Full Text] [Related]
12. Enterotoxigenic Escherichia coli Adhesin-Toxoid Multiepitope Fusion Antigen CFA/I/II/IV-3xSTa
Nandre R; Ruan X; Lu T; Duan Q; Sack D; Zhang W
Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29263112
[TBL] [Abstract][Full Text] [Related]
13. Split immune response after oral vaccination of mice with recombinant Escherichia coli Nissle 1917 expressing fimbrial adhesin K88.
Remer KA; Bartrow M; Roeger B; Moll H; Sonnenborn U; Oelschlaeger TA
Int J Med Microbiol; 2009 Nov; 299(7):467-78. PubMed ID: 19467927
[TBL] [Abstract][Full Text] [Related]
14. Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I.
Turner AK; Beavis JC; Stephens JC; Greenwood J; Gewert C; Thomas N; Deary A; Casula G; Daley A; Kelly P; Randall R; Darsley MJ
Infect Immun; 2006 Feb; 74(2):1062-71. PubMed ID: 16428753
[TBL] [Abstract][Full Text] [Related]
15. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
Jaganathan KS; Vyas SP
Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of thiolated eudragit microspheres as an oral vaccine delivery system to induce mucosal immunity against enterotoxigenic Escherichia coli in mice.
Lee WJ; Cha S; Shin M; Jung M; Islam MA; Cho CS; Yoo HS
Eur J Pharm Biopharm; 2012 May; 81(1):43-8. PubMed ID: 22306699
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.
Eldridge JH; Staas JK; Meulbroek JA; Tice TR; Gilley RM
Infect Immun; 1991 Sep; 59(9):2978-86. PubMed ID: 1879922
[TBL] [Abstract][Full Text] [Related]
18. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.
McKenzie R; Bourgeois AL; Engstrom F; Hall E; Chang HS; Gomes JG; Kyle JL; Cassels F; Turner AK; Randall R; Darsley M; Lee C; Bedford P; Shimko J; Sack DA
Infect Immun; 2006 Feb; 74(2):994-1000. PubMed ID: 16428745
[TBL] [Abstract][Full Text] [Related]
19. Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigens.
Fattal E; Pecquet S; Couvreur P; Andremont A
Int J Pharm; 2002 Aug; 242(1-2):15-24. PubMed ID: 12176221
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.
Qadri F; Akhtar M; Bhuiyan TR; Chowdhury MI; Ahmed T; Rafique TA; Khan A; Rahman SIA; Khanam F; Lundgren A; Wiklund G; Kaim J; Löfstrand M; Carlin N; Bourgeois AL; Maier N; Fix A; Wierzba T; Walker RI; Svennerholm AM
Lancet Infect Dis; 2020 Feb; 20(2):208-219. PubMed ID: 31757774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
